PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30317998-1 2019 BACKGROUND: Vortioxetine is a multimodal antidepressant drug with combined effects on SERT as an inhibitor, 5-HT1A as agonist and 5-HT3A as an antagonist. Vortioxetine 12-24 solute carrier family 6 member 4 Homo sapiens 86-90 31835640-1 2019 Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 104-125 31835640-1 2019 Vortioxetine is a novel, multimodal antidepressant with unique targets, including the inhibition of the serotonin transporter (SET), of serotonin 5-HT3 (5-HT3R), and of 5-HT7 (5-HT7R) receptors and partial agonism to serotonin 5-HT1A (5-HT1AR) receptors in humans. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 127-130 31678343-1 2020 The antidepressant drug vortioxetine has a multimodal action modulating neurotransmission through inhibition of the serotonin transporter and modulation of serotonin receptors. Vortioxetine 24-36 solute carrier family 6 member 4 Homo sapiens 116-137 30457395-6 2019 Expert opinion: Vortioxetine displays high affinity for serotonin transporter (SERT), and serotonin 5-HT3, 5HT1A, 5HT7 receptors. Vortioxetine 16-28 solute carrier family 6 member 4 Homo sapiens 56-77 30457395-6 2019 Expert opinion: Vortioxetine displays high affinity for serotonin transporter (SERT), and serotonin 5-HT3, 5HT1A, 5HT7 receptors. Vortioxetine 16-28 solute carrier family 6 member 4 Homo sapiens 79-83 30457395-7 2019 Functional studies show that vortioxetine acts as a SERT blocker, a 5-HT3, 5-HT7 receptor antagonist, and a 5-HT1A receptor agonist. Vortioxetine 29-41 solute carrier family 6 member 4 Homo sapiens 52-56 29189941-11 2018 Pharmacodynamic studies demonstrated that vortioxetine achieved high levels of serotonin transporter occupancy in relevant brain areas, affected neurotransmitter levels in the cerebrospinal fluid, and modified abnormal resting state networks in the brain over the therapeutic dose range. Vortioxetine 42-54 solute carrier family 6 member 4 Homo sapiens 79-100 30194544-25 2019 One third of inpatients and one half of outpatients had a significant therapeutic response to trazadone by the end of the first week with the remainder of patients responding in 2-4 weeks of therapy.Vortioxetine is a novel antidepressant classified by the World Health Organization as a N06AX antidepressant that was derived from studies targeting the combination of direct serotonin transporter inhibition and 5-HT1A receptor modulation leading to rapid desensitization of the somatodendritic 5-HT1A autoreceptors and activation of the postsynaptic 5-HT1A receptors. Vortioxetine 199-211 solute carrier family 6 member 4 Homo sapiens 374-395 28677828-5 2017 It is assumed that vortioxetine"s antidepressant action is related to a direct modulation of serotonergic receptor activity and inhibition of the serotonin transporter. Vortioxetine 19-31 solute carrier family 6 member 4 Homo sapiens 146-167 26702943-2 2016 The multimodal-acting antidepressant vortioxetine is an antagonist at 5-HT3, 5-HT7, and 5-HT1D receptors, a partial agonist at 5-HT1B receptors, an agonist at 5-HT1A receptors, and an inhibitor of the serotonin (5-HT) transporter (SERT) and has pro-cognitive properties. Vortioxetine 37-49 solute carrier family 6 member 4 Homo sapiens 231-235 27996982-2 2016 Vortioxetine is a multi-modal antidepressant that functions both as serotonin transporter (SERT) inhibitor and as 5-HT3, 5-HT7 and 5-HT1D receptors antagonist, 5-HT1A receptor agonist and 5-HT1B receptor partial agonist. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 68-89 27996982-2 2016 Vortioxetine is a multi-modal antidepressant that functions both as serotonin transporter (SERT) inhibitor and as 5-HT3, 5-HT7 and 5-HT1D receptors antagonist, 5-HT1A receptor agonist and 5-HT1B receptor partial agonist. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 91-95 28692076-6 2017 A novel antidepressant, with a multimodal mechanism of action that combines the classical inhibition of serotonin transporter (SERT) with the modulation of serotonin receptor activity, is vortioxetine. Vortioxetine 188-200 solute carrier family 6 member 4 Homo sapiens 104-125 28692076-6 2017 A novel antidepressant, with a multimodal mechanism of action that combines the classical inhibition of serotonin transporter (SERT) with the modulation of serotonin receptor activity, is vortioxetine. Vortioxetine 188-200 solute carrier family 6 member 4 Homo sapiens 127-131 25016186-1 2015 Vortioxetine, a novel antidepressant for the treatment of major depressive disorder (MDD), is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 232-236 26174134-2 2015 Vortioxetine, a multimodal antidepressant acting through serotonin (5-HT) transporter (SERT) inhibition, 5-HT3, 5-HT7 and 5-HT1D receptor antagonism, 5-HT1B receptor partial agonism, and 5-HT1A receptor agonism, had fewer incidences of sleep-related adverse events reported in depressed patients. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 87-91 26389667-0 2015 Binding of the multimodal antidepressant drug vortioxetine to the human serotonin transporter. Vortioxetine 46-58 solute carrier family 6 member 4 Homo sapiens 72-93 26389667-3 2015 Vortioxetine represents a new class of antidepressant drugs with a multimodal pharmacological profile that in addition to potent inhibition of hSERT include agonistic or antagonistic effects at different serotonin receptors. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 143-148 26389667-4 2015 We used a combination of computational, chemical, and biological methods to decipher the molecular basis for high affinity binding of vortioxetine in hSERT. Vortioxetine 134-146 solute carrier family 6 member 4 Homo sapiens 150-155 26389667-6 2015 Comparative modeling and ligand docking suggest that vortioxetine can adopt several distinct binding modes within the central binding site of hSERT. Vortioxetine 53-65 solute carrier family 6 member 4 Homo sapiens 142-147 26389667-9 2015 The findings provide important new insight about the molecular basis for high affinity recognition of vortioxetine in hSERT, which is essential for future structure-based drug discovery of novel multimodal drugs with fine-tuned selectivity across different transporter and receptor proteins in the human brain. Vortioxetine 102-114 solute carrier family 6 member 4 Homo sapiens 118-123 26253622-7 2015 The relation between REM suppression parameters and SERT occupancy was significantly different between vortioxetine and paroxetine, despite the same SERT occupancy. Vortioxetine 103-115 solute carrier family 6 member 4 Homo sapiens 52-56 26035185-1 2015 CONTEXT: Vortioxetine (Lu AA21004) is an antidepressant with a mechanism of action thought to be related to a combination of 2 pharmacologic actions: direct modulation of several receptors and inhibition of the serotonin transporter. Vortioxetine 9-21 solute carrier family 6 member 4 Homo sapiens 211-232 26035186-2 2015 The mechanism of action of vortioxetine is thought to be related to direct modulation of serotonin (5-HT) receptor activity and inhibition of the serotonin transporter. Vortioxetine 27-39 solute carrier family 6 member 4 Homo sapiens 146-167 24165478-6 2014 DATA SYNTHESIS: Vortioxetine is a multi-modal antidepressant that functions as a human 5-HT3A and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and inhibitor of the serotonin transporter. Vortioxetine 16-28 solute carrier family 6 member 4 Homo sapiens 204-225 25075188-1 2014 VORTIOXETINE IS A NEW MULTIMODAL ACTION ANTIDEPRESSANT WITH TWO TYPES OF ACTION: serotonin transporter (SERT) blockade and a strong affinity for several serotoninergic receptors. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 81-102 25075188-1 2014 VORTIOXETINE IS A NEW MULTIMODAL ACTION ANTIDEPRESSANT WITH TWO TYPES OF ACTION: serotonin transporter (SERT) blockade and a strong affinity for several serotoninergic receptors. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 104-108 24570588-1 2014 Vortioxetine is a novel antidepressant with effects on multiple 5-HT receptors and on the serotonin transporter. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 90-111 33587394-2 2021 Vortioxetine, a recently developed antidepressant, acts as a serotonin modulator through inhibition of the serotonin transporter and actions at multiple types of serotonin receptors. Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 107-128 23428337-0 2013 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). Vortioxetine 61-73 solute carrier family 6 member 4 Homo sapiens 0-5 33572981-3 2021 A member of a novel class of antidepressants, vortioxetine, which is a serotonin partial agonist reuptake inhibitor (SPARI), also exhibits a higher affinity for serotonin transporter, serotonin receptors type 1A (5-HT1AR) and type 3 (5-HT3R), and 5-HT7R. Vortioxetine 46-58 solute carrier family 6 member 4 Homo sapiens 161-182 33572981-10 2021 These results indicate that chronic administration of vortioxetine, escitalopram, and lurasidone generate downregulation of 5-HT7R in the thalamus; however, the direct inhibition of 5-HT7R associated with vortioxetine and lurasidone generates more rapid downregulation than the indirect elevation of the extracellular serotonin level via serotonin transporter inhibition by escitalopram. Vortioxetine 54-66 solute carrier family 6 member 4 Homo sapiens 338-359 32750222-1 2020 Vortioxetine is a potent antagonist of the 5-hydroxytryptamine (5-HT) receptor and serotonin transporter (SERT), and has been reported to function as an antidepressant for treatment of major depressive disorder (MDD). Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 83-104 32750222-1 2020 Vortioxetine is a potent antagonist of the 5-hydroxytryptamine (5-HT) receptor and serotonin transporter (SERT), and has been reported to function as an antidepressant for treatment of major depressive disorder (MDD). Vortioxetine 0-12 solute carrier family 6 member 4 Homo sapiens 106-110